The studies demonstrated proof-of-concept that absorption of the drug was greater than with the same dose of oral vitamin administered alone. Emisphere expects to begin clinical human trials in the third quarter of 2008.

eligen(R) is based on the use of proprietary, synthetic chemical compounds, known as EMISPHERE(R) delivery agents. These delivery agents facilitate transport of therapeutic macromolecules across biological membranes.

Source: Emisphere Technologies, Inc.